Annals On Call - COVID-19 Rebound After Nirmatrelvir–Ritonavir Treatment
Authors: Robert M. Centor, Myron S. Cohen
Journal: Annals of Internal Medicine (2024)

Web ExclusivesJanuary 2024Annals On Call - COVID-19 Rebound After Nirmatrelvir–Ritonavir TreatmentFREERobert M. Centor, MD, and Myron S. Cohen, MDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author, and Myron S. Cohen, MDInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (M.S.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A23-0002 CME/MOC SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses rebound of COVID-19 after treatment with nirmatrelvir–ritonavir with Dr. Myron Cohen.Annals articles discussed include...SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy: An Observational Study: https://www.acpjournals.org/doi/10.7326/M23-1756Rebound of COVID-19 With Nirmatrelvir–Ritonavir Antiviral Therapy: https://www.acpjournals.org/doi/10.7326/M23-2887About Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Robert M. Centor, MD; Myron S. Cohen, MDAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (M.S.C.)Disclosures: All relevant financial relationships have been mitigated. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=A23-0002.Editors' Disclosures: The editors have no relevant financial relationships to disclose. Individual forms may be viewed at www.annals.org/editorsdisclosures. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy Gregory E. Edelstein , Julie Boucau , Rockib Uddin , Caitlin Marino , May Y. Liew , Mamadou Barry , Manish C. Choudhary , Rebecca F. Gilbert , Zahra Reynolds , Yijia Li , Dessie Tien , Shruti Sagar , Tammy D. Vyas , Yumeko Kawano , Jeffrey A. Sparks , Sarah P. Hammond , Zachary Wallace , Jatin M. Vyas , Amy K. Barczak , Jacob E. Lemieux , Jonathan Z. Li , and Mark J. Siedner Rebound of COVID-19 With Nirmatrelvir–Ritonavir Antiviral Therapy Myron S. Cohen , Elizabeth R. Brown Metrics Current Issue January 2024Volume 177, Issue 1 ePublished: 16 January 2024 Issue Published: January 2024 Copyright & PermissionsCopyright © 2024 by American College of Physicians. All Rights Reserved.Loading ...